The Golden Helix Foundation, London, WC2N 5AP, UK.
GeneYouIn Inc., Toronto, ON, M5B 2L7, Canada.
Pharmacogenomics. 2020 Jul;21(11):797-807. doi: 10.2217/pgs-2019-0194. Epub 2020 Jul 8.
The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, individualized clinical interventions that maximize efficacy and/or minimize the risk of adverse drug reactions. In order to ensure equal access to genomic testing for all patients, the costs associated with these interventions must be reimbursed by payers and insurance bodies. As such, it is of utmost importance to thoroughly evaluate these interventions both in terms of their clinical effectiveness and their economic cost. This article discusses the impact of personalized medicine interventions in terms of both health outcomes and value, which directly impacts on their pricing and reimbursement by the various national healthcare systems.
将个性化医学干预措施纳入常规医疗保健中,为提高患者的生活质量提供了机会,因为它使实施创新的个体化临床干预措施成为可能,这些干预措施可以最大限度地提高疗效和/或降低药物不良反应的风险。为确保所有患者都能平等获得基因组检测,支付方和保险公司必须报销这些干预措施的相关费用。因此,彻底评估这些干预措施在临床效果和经济成本方面的效果至关重要。本文讨论了个性化医学干预措施在健康结果和价值方面的影响,这直接影响到它们在各种国家医疗保健系统中的定价和报销。